Abstract:In recent years, much attention has been given to fibroblast growth factor (FGF)21 and its role as a metabolic regulator, both of specific organs and the mammalian organism as a whole. Interest was sparked in 2005, when Kharitonenkov et al (1) discovered that FGF21 had profound positive effects on glucose uptake, lipid clearance, and insulin levels and that elevating FGF21 protein levels was protective against dietinduced obesity in mice. Since this discovery, human studies haveconsistently shownthat circulating levelsofFGF21correlate with obesity and the metabolic syndrome (2, 3), whereas murine studies confirm this phenotypic relationship and support the premise that obesity represents an FGF21resistant state (4, 5). These findings have fueled excitement for the possibility of exploiting FGF21 or its signaling pathways therapeutically in target tissues. Indeed, early trials using FGF21 analogs have already shown promising results, with2compounds todatebeingeffectiveat improvingserum lipid profiles and markers of cardiovascular disease risk, while reducing body weight in obese diabetic patients (6, 7). FGF21 regulates these distinct yet closely related components of metabolism through its ability to influence key metabolic pathways in multiple tissues, in a coordinated fashion. Although most FGF proteins work by exerting autocrine/paracrine effects on cell growth, division and mitosis, the structure of the “atypical” FGF proteins (FGF19, FGF21, and FGF23) enables their secretion, circulation and endocrine actions (8). The liver is the primary site of FGF21 production, with expression also detected in muscle and brown adipose tissue (BAT) under certain conditions (9–12). Although FGF receptors (FGFR) are expressed in a wide range of tissues, its sites of action are inferred by the more restricted expression profile of FGF21’s essential coreceptor, -Klotho (13). -Klotho is expressed at the highest levels in liver and adipose tissues, followed by pancreas and the colon, where it complexes with FGFR1–FGFR4 to form receptors for FGF21 (14). The physiological role of FGF21 in these tissues has been detailed extensively in a previous review of the subject (15), but in summary, it regulates the adaptive response to fasting via its induction in states that require increased fatty acid oxidation. Interestingly, however, FGF21 also enhances glucose uptake in the fed state via up-regulation of the insulin-independent glucose transporter 1 and increases lipid handling and oxidation pathways in liver and adipose tissues via peroxisome proliferator-activated receptorcoactivator 1 (16–18). As such, it has been suggested that just as insulin and glucagon coordinate acute responses to changes in nutrient availability, FG21 and its relative FGF19 (FGF15 in mice) regulate longer term adaptive changes to energy scarcity or excess (15). It is somewhat of an understatement to say that, after almost a century of research, the complexities of insulin signaling are still not fully understood. Therefore it is highly likely that thephysiologyandregulationofFGF21signaling, as an adaptive regulator of metabolism and fuel substrate utilization in multiple tissues, is equally complex and caveatridden. Much of what is known comes from studies of mice that completely lack FGF21, or those that have increased circulating amounts of the protein. These models show clearly that FGF21 plays an important role in glucose homeostasis, energy balance, BAT thermogenesis and lipid clearance, particularly during fasted and overfed states (1, 17, 19). Treatment studies have identified powerful roles for FGF21 in BAT, where it acts as the activation signal for ther-

Hepatic Sel1L‐Hrd1 ER‐associated degradation (ERAD) manages FGF21 levels and systemic metabolism via CREBH

Hepatic Endoplasmic Reticulum Associated Degradation (ERAD) Manages FGF21 Levels and Metabolism Via CREBH During Fasting‐feeding and Growth

HRD1‐ERAD Controls Production of the Hepatokine FGF21 Through CREBH Polyubiquitination

Fibroblast Growth Factor 21 is Regulated by the IRE1α-XBP1 Branch of the Unfolded Protein Response and Counteracts Endoplasmic Reticulum Stress-Induced Hepatic Steatosis.

Fasting-induced hormonal regulation of lysosomal function

FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

Regulation of hepatic circadian metabolism by the E3 ubiquitin ligase HRD1-controlled CREBH/PPARα transcriptional program

Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase

Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice

Nutritional Regulation of Hepatic FGF21 by Dietary Restriction of Methionine

FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.

Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway

FGF21 Conducts a Metabolic Orchestra and Fat Is a Key Player.

ER-associated Ubiquitin Ligase HRD1 Programs Liver Metabolism by Targeting Multiple Metabolic Enzymes

FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance.

Fibroblast Growth Factor 21 Induces Glucose Transporter-1 Expression through Activation of the Serum Response Factor/Ets-Like Protein-1 in Adipocytes*

Liver-derived Fibroblast Growth Factor 21 Mediates Effects of Glucagon-Like Peptide-1 in Attenuating Hepatic Glucose Output

Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk

Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice